New leukemia drug trial seeks better control for Tough-to-Treat blood cancer
NCT ID NCT07033598
Summary
This study is comparing two drugs, pacritinib and hydroxyurea, to see which one better controls an advanced form of chronic myelomonocytic leukemia (CMML), a type of blood cancer. About 66 adults with this condition will be randomly assigned to take one of the drugs for up to 48 weeks. The main goal is to see if pacritinib improves blood counts, reduces spleen size, and eases symptoms better than the current standard treatment, hydroxyurea.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOMONOCYTIC, CHRONIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Email: •••••@•••••
-
Mayo Clinic Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-••••
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Email: •••••@•••••
Contact
-
Winship Cancer Institute at Emory
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.